Wound Management Technologies, Inc, Fort Worth, Texas, announced today that 45 new clinicians are evaluating their advanced wound care collagen product, CellerateRx, resulting in increased usage throughout a number of states. Cathy Bradshaw, president of Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc, said, "We are excited about the number of new clinicians using CellerateRx. This has also resulted in an increase in the number of new distributors of our product around the country."
CellerateRx is a patented collagen product that is Food and Drug Administration approved for market for all acute and chronic wounds, except third-degree burns.
STB Lifesaving Technologies, Rockville, Maryland, announced that $2.4 million was included in the FY2010 US Department of Defense appropriations bill to advance the development of the Fibrin Adhesive STat dressing. This newly developed dressing is designed to be effective against all kinds of blood loss, including severe arterial and venous bleeding, and could help save the lives of soldiers suffering from severe blood loss. According to the Combat Casualty Care Research Program, 86% of combat-related deaths occur within 30 minutes of wounding, and 50% or more are attributable to uncontrolled hemorrhaging.